Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 12/20 | 0.55 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16473229 | 0.88 | TGFBR1 (0.56) | TRPA1TGFBR1EGFRTRPM8CSNK1E | |
| SCHEMBL16473228 | 0.84 | TRPA1 (0.51) | TRPA1TGFBR1TRPM8 | |
| SCHEMBL16473225 | 0.82 | TRPA1 (0.70) | TRPA1TGFBR1TRPM8 | |
| SCHEMBL15639196 | 0.82 | TGFBR1 (0.53) | TRPA1TGFBR1TRPM8 | |
| SCHEMBL16473230 | 0.81 | TGFBR1 (0.54) | TRPA1TGFBR1TRPM8 | |
| SCHEMBL16473226 | 0.77 | TRPA1 (0.54) | TRPA1TGFBR1TRPM8 | |
| SCHEMBL15639504 | 0.75 | TGFBR1 (0.53) | TRPA1TGFBR1TRPM8 | |
| SCHEMBL22753052 | 0.74 | TGFBR1 (0.57) | TRPA1TGFBR1S1PR1FGFR1TRPM8 | |
| SCHEMBL30117487 | 0.73 | TGFBR1 (0.71) | TRPA1TGFBR1TRPM8 | |
| SCHEMBL15638898 | 0.73 | TGFBR1 (0.71) | TRPA1TGFBR1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9878992-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170096409-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | MIDCAP FINANCIAL TRUST | 2017-04-06 | — | — | US | disclosed |
| US-9145433-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140107073-A1 | GDF-8 Inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107073-A1 | GDF-8 Inhibitors | MSTN, MYOF, CXCL8 | TRPA1 4474/4885TGFBR1 128/4885EGFR 743/4885 |
| US-20170096409-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | TGFBR1, TGFBR2, ACVR1 | TRPA1 4073/4885TGFBR1 1/4885EGFR 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.